Shares of Forest Laboratories jumped on the news that FDA staffers found that their new antibiotic ceftaroline appears to be an effective therapy for skin infections and pneumonia. The staff review comes in advance of a key panel vote on the new antibiotic. Analysts have estimated that ceftaroline could garner $361 million in sales by 2014. Story